Subject(s)
Humans , Child , Asthma/drug therapy , Adrenal Cortex Hormones/administration & dosage , Pregnadienediols/administration & dosage , Pregnadienediols/adverse effects , Pregnenediones/administration & dosage , Pregnenediones/adverse effects , Administration, Inhalation , Beclomethasone/administration & dosage , Beclomethasone/adverse effects , Review Literature as Topic , Randomized Controlled Trials as Topic , Meta-Analysis as Topic , Adrenal Cortex Hormones/adverse effects , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/adverse effects , Budesonide/administration & dosage , Budesonide/adverse effects , Dose-Response Relationship, Drug , Fluticasone , Mometasone Furoate , Systematic Reviews as Topic , Growth/drug effects , Growth Disorders/chemically induced , Androstadienes/administration & dosage , Androstadienes/adverse effectsABSTRACT
<p><b>OBJECTIVE</b>To analyze the clinical feature and treatment methods of Artemisia pollinosis.</p><p><b>METHODS</b>Skin prick test results of 14 426 cases from Beijing Tongren hospital and pollen concentration of Beijing observatory from 2007 to 2011 were analyzed to identify the clinical feature of Artemisia pollinosis patients and its correlation with the pollen concentration. Patients were given leukotriene receptor antagonists (Montelukast) for 2 weeks, followed by 4 weeks of mometasone furoate nasal spray (EIT group: n = 21), or only 4 weeks of mometasone furoate nasal spray (POT group: n = 16). The nasal symptom score was compared between 2 groups.SPSS 16.0 software was used to analyze the data.</p><p><b>RESULTS</b>Artemisia pollinosis accounted for 30.8% (4 442/14 426) of all SPT positive allergic rhinitis patients, and most Artemisia SPT positive results were strong positive(3 793/4 442, 85.4%); onset age peak of Artemisia pollinosis patients was at the age of 19 to 30, onset time concentrated in August to September, was consistent with the peak period of Artemisia pollen concentration; EIT treatment using leukotriene receptor antagonists two weeks before pollen season significantly improved sneeze, sniveling and rhinocnesmus symptoms (t value was 3.28, 3.92, 3.09, respectively, all P < 0.01) compared with post-onset treatment (POT). But nasal obstruction and cough symptoms had no significant difference between two groups (t value was 0.85, 1.52, respectively, all P > 0.05).</p><p><b>CONCLUSION</b>Artemisia pollen is the main pollen allergen in Beijing, EIT treatment was effective to pollinosis.</p>
Subject(s)
Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Young Adult , Acetates , Therapeutic Uses , Age of Onset , Allergens , Allergy and Immunology , Artemisia , China , Mometasone Furoate , Pollen , Allergy and Immunology , Pregnadienediols , Therapeutic Uses , Quinolines , Therapeutic Uses , Rhinitis, Allergic, Seasonal , Diagnosis , Drug Therapy , Seasons , Treatment OutcomeABSTRACT
<p><b>OBJECTIVE</b>To explore the treatment methods of pediatric obstructive sleep apnea hypopnea syndrome (OSAHS).</p><p><b>METHODS</b>A total of 386 children with OSAHS were enrolled from June 2008 to April 2011.Ninety children with adenoid and tonsil ≤ degree III (group A) were randomly divided into A1 subgroup and A2 subgroup, while 22 of 296 (group B) children aged less than 3 years old with degree IV adenoid and(or) tonsil were divided into B1 subgroup, and the other 274 of 296 children with degree IV adenoid and (or) tonsil were divided into B1 subgroup, B2 subgroup and B3 subgroup. The adenoid, tonsil size examination and nasal endoscopic examination scores were performed before treatment, 3 months and 6 months after treatment. Drug therapy included oral antibiotics, mometasone furoate as a nasal spray, leukotriene receptor antagonist (LTRAs), mucoactive medications. Conservative treatment meant drug therapy plus negative pressure of sputum aspiration.Surgical treatment meant coblation adenotonsillectomy. A1 subgroup received drug therapy for 3 months; A2 and B1 subgroup received conservative treatment for 3 months; B2 subgroup received coblation adenotonsillectomy after 3 days conservative treatment and postoperative drug therapy for 2 weeks; B3 subgroup received coblation adenotonsillectomy after 2 weeks conservative treatment and postoperative drug therapy for 3 months.</p><p><b>RESULTS</b>The adenoid and tonsil size of A2 subgroup decreased at 3 months after treatment (Wald χ² were 10.584 and 8.366, respectively, P < 0.05), no significant re-increase was found at 6 months, and no decrease was found in the A1 subgroup (P > 0.05). The nasal endoscopic examination scores decreased in both A1 and A2 subgroup at 3 months after the treatment (F = 403.420, P < 0.05), but it was found re-increase in A1 subgroup at the 6 months (P < 0.05), no significant re-increase was found in the A2 subgroup. The polysomnography (PSG) monitor of A2 subgroup was 100.0% normal at 3 months after treatment, while the A1 subgroup was only 43.2% (χ² = 36.189, P < 0.05). B2 and B3 subgroups cured after coblation adenotonsillectomy, but no decrease of the adenoid and tonsil size was found in B1 subgroup (P > 0.05). The nasal endoscopic examination scores of B1, B2 and B3 subgroups showed significant decrease after the treatment, but re-increase was found in both B1 and B2 subgroups at the 6 months (F = 1 614.244, P < 0.05), no significant re-increase was found in the B3 subgroup. The PSG monitor of B3 subgroup was 100.0% normal at 3 months after treatment, B2 subgroup 73.4%, and B1 subgroup only 57.4% (χ² = 90.846, P < 0.05).</p><p><b>CONCLUSIONS</b>The treatment method of children with OSAHS should be selected according to the age, condition of disease, and size of the adenoid and tonsil. Adenoid and tonsil ≤ degree III should select conservative treatment; while for degree IV adenoid and (or) tonsil, surgical treatment should be primary choice. Conservative treatment can reduce the risk of perioperative and adequate postoperative drug therapy can help prevent recurrence after surgery.</p>
Subject(s)
Child , Humans , Adenoidectomy , Adenoids , Mometasone Furoate , Palatine Tonsil , Polysomnography , Pregnadienediols , Recurrence , Sleep Apnea, Obstructive , Therapeutics , TonsillectomyABSTRACT
BACKGROUND: Topical application of corticosteroids also has an influence on skin barrier impairment. Physiological lipid mixtures, such as multi-lamellar emulsion (MLE) containing a natural lipid component leads to effective recovery of the barrier function. OBJECTIVE: The purpose of this study was to conduct an evaluation of the therapeutic efficacy and skin barrier protection of topical mometasone furoate in MLE. METHODS: A multi-center randomized, double-blind, controlled study was performed to assess the efficacy and safety of mometasone furoate cream in MLE for Korean patients with eczema. The study group included 175 patients with eczema, who applied either mometasone furoate in MLE cream or methylprednisolone aceponate cream for 2 weeks. Treatment efficacy was evaluated using the physician's global assessment of clinical response (PGA), trans-epidermal water loss (TEWL), and visual analogue scale (VAS) for pruritus. Patients were evaluated using these indices at days 4, 8, and 15. RESULTS: Comparison of PGA score, TEWL, and VAS score at baseline with those at days 4, 8, and 15 of treatment showed a significant improvement in both groups. Patients who applied mometasone furoate in MLE (74.8%) showed better results (p<0.05) than those who applied methylprednisolone aceponate (47.8%). The TEWL improvement ratio was higher in the mometasone furoate in MLE group than that in the methylprednisolone aceponate group, and VAS improvement was also better in the mometasone furoate in MLE group. CONCLUSION: Mometasone furoate in MLE has a better therapeutic efficacy as well as less skin barrier impairment than methylprednisolone aceponate.
Subject(s)
Humans , Adrenal Cortex Hormones , Cross-Over Studies , Eczema , Methylprednisolone , Pregnadienediols , Prostaglandins A , Pruritus , Skin , Treatment Outcome , Water Loss, Insensible , Mometasone FuroateABSTRACT
OBJECTIVES: To investigate the effect of rhinophototherapy with medical therapy on quality of life in persistent allergic rhinitis. METHODS: A prospective, randomized study was being performed between December 2009 and March 2010. The study included 65 patients with persistent allergic rhinitis. The diagnosis was confirmed with positive skin tests. All of the patients had house dust mite allergies. We divided the patients into two groups. First group (n=33) was given topical mometasone furoate 200 mcg/day and levocetirizine 5 mg/day for a month. Rhinophototherapy was applied with the same medical therapy to the second group (n=32), twice a week for three weeks continuously. Rhinophototherapy included visible light, ultraviolet A and ultraviolet B. We evaluated patients before the treatment, at the first month and at the third month after treatment with rhinoconjunctivitis quality of life questionnaire, nasal symptom scores and visual analogue scale (VAS) scores. RESULTS: Improvements of all variables of the quality of life questionnaire, nasal symptom scores and VAS were statistically significant in the second group both on the first and the third months when compared with the first group. CONCLUSION: Allergic rhinitis is a social problem and impairs quality of life. Rhinophototherapy with medical therapy improves the quality of life in allergic rhinitis.
Subject(s)
Humans , Cetirizine , Hypersensitivity , Light , Pregnadienediols , Prospective Studies , Pyroglyphidae , Quality of Life , Rhinitis , Rhinitis, Allergic, Perennial , Skin Tests , Social Problems , Mometasone Furoate , Surveys and QuestionnairesABSTRACT
BACKGROUND: Vitiligo is a prevalent skin pigmentation disorder worldwide. The treatments available still offer limited results to some patients. For patients with clinically stable vitiligo, melanocyte transplantation is an appropriate treatment option, and the technique of autologous punch grafting shows good repigmentation. OBJECTIVE: To evaluate the effect of topical mometasone on the halos of repigmentation after autologous punch grafting in patients with clinically stable vitiligo. METHODS: Between 2009 and 2010, 11 patients with clinically stable vitiligo (7 generalized, 2 focal and 2 segmental) underwent autologous punch grafting in the achromic patches. According to the clinical type of vitiligo, patients were instructed to use the corticosteroid ointment during 6 months, only on a few grafted lesions. In the first month, the mometasone ointment was used twice a day and after that just once. They were reassessed 1, 3 and 6 months after the procedure. Grafted halos were photographed and recorded using the software fotofinder. After 6 months, all the treated and untreated areas of the repigmentation halos were measured and analyzed comparatively. RESULTS: The median area of the repigmentation halos after 6 months of treatment with mometasone was larger (25,96 mm² ) than the one of the untreated halos (13,86 mm² ), showing a statistically significant difference (p = 0,026). CONCLUSION: In this study, the use of mometasone ointment increased the area of the repigmentation halos after punch grafting. However, this should be further investigated in larger samples in order to validate this positive action in the treatment of stable vitiligo.
FUNDAMENTOS: Vitiligo é um transtorno de pigmentação freqüente na população mundial. Seu tratamento ainda oferece resultados limitados em alguns pacientes. Nos casos de vitiligo estável clinicamente, o transplante de melanócitos tornase uma opção terapêutica, sendo a técnica de enxertos autólogos por punch empregada com boa resposta na repigmentação. OBJETIVOS: Estudar a ação do corticoesteróide tópico mometasona sobre halos de repigmentação após enxertos autólogos por punch em pacientes com vitiligo estável clinicamente. MÉTODOS: Entre 2009 e 2010, 11 pacientes com vitiligo estável (7 do tipo generalizado, 2 focal e 2 segmentar) foram submetidos a enxertos autólogos por punch nas máculas acrômicas. Conforme o tipo clínico do vitiligo, os pacientes eram orientados a aplicar pomada de mometasona por 6 meses em lesões enxertadas selecionadas individualmente. No primeiro mês, a aplicação era 2 vezes ao dia e nos demais, apenas uma vez ao dia. Eram reavaliados nos meses 1, 3 e 6 após enxertos cujos halos eram fotografados e registrados pelo software fotofinder. No fim do 6̊mês, todas as áreas dos halos de repigmentação com e sem mometasona foram mensuradas e analisadas comparativamente. RESULTADOS: A mediana da área dos halos de repigmentação após os 6 meses com mometasona foi superior (25,96 mm² ) comparada àquela sem mometasona (13,86 mm² ), com diferença estatisticamente significante (p=0,026). CONCLUSÃO: Em nossa casuística, o uso da mometasona tópica determinou incremento dos halos de repigmentação após enxertia. A amplificação da amostra se faz necessária em estudos posteriores a fim de ratificar esta ação positiva da mometasona no tratamento do vitiligo estável.
Subject(s)
Adolescent , Adult , Aged , Female , Humans , Middle Aged , Young Adult , Anti-Inflammatory Agents/therapeutic use , Epidermis/transplantation , Pregnadienediols/therapeutic use , Skin Transplantation , Skin Pigmentation/drug effects , Vitiligo/therapy , Combined Modality Therapy/methods , Transplantation, Autologous , Treatment OutcomeABSTRACT
OBJECTIVE@#To compare the effect of the medical and surgical treatment of pediatric chronic rhinosinusitis (CRS).@*METHOD@#Seventy-two cases of pediatric CRS were randomly divided into medical group (35 cases) and surgical group (37 cases). The patients in medical group received a 12-week course of clarithromycin, alkaline nasal douche and intranasal mometasone furoate. The patients in surgical group underwent adenoidectomy or (and) tonsillectomy or ESS. All patients underwent pre- and post-treatment assessments of visual analogue score (VAS) and nasal endoscopy. The assessments of CT were arranged before starting the treatment and post-treatment in 12-month.@*RESULT@#Both groups of pediatric CRS significantly improved in VAS and endoscopic parameters of CRS in all stages. There were no significant difference between two groups in 1-month (P > 0.05). The surgical group demonstrated greater change than medical group in 3-month, 6-month and 12-month (P < 0.01). In surgical group, 37 cases underwent three different styles of operation: adenoidectomy (n = 19), adenoidectomy and tonsillectomy (n = 10) and ESS (n = 8). VAS and endoscopic parameters were not significantly different among three groups in all stages except in 1-month.@*CONCLUSION@#The results of this study warrant further that both medical and surgical treatment of pediatric CRS significantly improve in VAS and endoscopic parameters of CRS. The mainstay of management is medical treatment. Long-term, low-dose macrolide is an effective therapy and a valid alternative in pediatric CRS. Surgical intervention is necessary for cases that do not respond to prolonged course medical treatment. Adenoidectomy or (and) tonsillectomy seems to be a recommended surgical procedure for children with adenoid or (and) tonsil hypertrophy.
Subject(s)
Adolescent , Child , Female , Humans , Male , Adenoidectomy , Chronic Disease , Clarithromycin , Therapeutic Uses , Mometasone Furoate , Pregnadienediols , Therapeutic Uses , Sinusitis , Drug Therapy , General Surgery , Tonsillectomy , Treatment OutcomeABSTRACT
OBJECTIVES: To evaluate efficacy of short term intranasal corticosteroid (mometasone furoate) treatment in pediatric sleep-disordered breathing (SDB) patients. METHODS: A prospective, observational study was done. A total of 41 children (2-11 years old) were enrolled into this study. All patients received 4-weeks course of mometasone furoate 100 microg/day treatment. They were evaluated at pretreatment and immediately after treatment with obstructive sleep apnea (OSA)-18 quality of life survey and lateral neck X-ray. Also, the assessment of each patients included history, skin prick test or CAP test, and sinus radiography. We compared the OSA-18 survey score and adenoidal-nasopharyngeal (AN) ratio between before and after treatment. RESULTS: Total OSA-18 score and AN ratio decreased significantly after treatment regardless of allergy, sinusitis, and obesity (P=0.003, P=0.006). There was no complication after treatment of mometasone furoate. CONCLUSION: Pediatric SDB patients with adenoid hypertrophy could be effectively treated with 4-weeks course of mometasone furoate. Allergy, obesity, and sinusitis did not affect on the result of treatment.
Subject(s)
Child , Humans , Adenoids , Administration, Topical , Hypersensitivity , Hypertrophy , Neck , Obesity , Pediatrics , Pregnadienediols , Prospective Studies , Quality of Life , Sinusitis , Skin , Sleep Apnea Syndromes , Sleep Apnea, Obstructive , Treatment Outcome , Mometasone FuroateABSTRACT
OBJECTIVES: To evaluate efficacy of short term intranasal corticosteroid (mometasone furoate) treatment in pediatric sleep-disordered breathing (SDB) patients. METHODS: A prospective, observational study was done. A total of 41 children (2-11 years old) were enrolled into this study. All patients received 4-weeks course of mometasone furoate 100 microg/day treatment. They were evaluated at pretreatment and immediately after treatment with obstructive sleep apnea (OSA)-18 quality of life survey and lateral neck X-ray. Also, the assessment of each patients included history, skin prick test or CAP test, and sinus radiography. We compared the OSA-18 survey score and adenoidal-nasopharyngeal (AN) ratio between before and after treatment. RESULTS: Total OSA-18 score and AN ratio decreased significantly after treatment regardless of allergy, sinusitis, and obesity (P=0.003, P=0.006). There was no complication after treatment of mometasone furoate. CONCLUSION: Pediatric SDB patients with adenoid hypertrophy could be effectively treated with 4-weeks course of mometasone furoate. Allergy, obesity, and sinusitis did not affect on the result of treatment.
Subject(s)
Child , Humans , Adenoids , Administration, Topical , Hypersensitivity , Hypertrophy , Neck , Obesity , Pediatrics , Pregnadienediols , Prospective Studies , Quality of Life , Sinusitis , Skin , Sleep Apnea Syndromes , Sleep Apnea, Obstructive , Treatment Outcome , Mometasone FuroateABSTRACT
OBJECTIVE@#To evaluate the effects of nasal mometasone furoate on oral and nasal nitric oxide (NO) production in patients with allergic rhinitis.@*METHOD@#Twenty-seven patients with moderate to severe symptoms of persistent allergic rhinitis were treated with mometasone furoate nasal spray (200 microg/d. qd) for 2 weeks. Nasal and oral exhaled nitric oxide concentrations, symptoms of rhinitis and quality of life were investigated before and after the treatment.@*RESULT@#There was a significant improvement in nasal exhaled nitric oxide concentrations, symptoms of rhinitis and quality of life, but not in oral exhaled nitric oxide concentrations. Subjective improvements in symptoms and quality of life did not correlate significantly with objective measurements.@*CONCLUSION@#Our study provides subjective and objective evidence on the efficacy of intranasal mometasone furoate in improving nasal symptoms and quality of life, as well as reducing nasal inflammation.
Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Administration, Intranasal , Anti-Allergic Agents , Therapeutic Uses , Mometasone Furoate , Nitric Oxide , Metabolism , Pregnadienediols , Therapeutic Uses , Quality of Life , Rhinitis, Allergic, Perennial , Drug Therapy , Metabolism , Rhinitis, Allergic, Seasonal , Drug Therapy , MetabolismABSTRACT
OBJETIVO: O furoato de mometasona (FM) é um novo corticosteroide inalatório sintético potente. Internacionalmente, o FM é fornecido em um inalador de pó seco que permite sua administração em múltiplas doses. Para se obter uma preparação com melhor relação custo-eficácia, foram desenvolvidas no Brasil formulações de FM em cápsulas de pó seco para serem administradas em dose única. O presente estudo teve como objetivo avaliar a eficácia e a segurança dos dois inaladores usados para a administração de FM em pacientes asmáticos. MÉTODOS: Estudo clínico, aberto, comparativo, paralelo e multicêntrico com 74 adultos portadores de asma persistente e moderada, randomizados em dois grupos para receber FM em uma dose de aproximadamente 400 µg, fornecida por um inalador de dose múltipla ou pelo novo inalador de dose única, uma vez ao dia durante 60 dias. RESULTADOS: Não foram observadas diferenças significantes entre os dois grupos estudados nos desfechos primários (VEF1 e frequência do uso de medicação de resgate) ou nos desfechos secundários (PFE matinal, tolerabilidade e segurança, essa última avaliada pelo estudo do eixo hipotálamo-hipófise-adrenal). CONCLUSÕES: A administração de FM com o novo inalador de dose única desenvolvido no Brasil tem eficácia e segurança comparáveis à administração com o inalador de dose múltipla no tratamento de pacientes asmáticos.
OBJECTIVE: Mometasone furoate (MF) is a new, potent synthetic inhaled corticosteroid. Worldwide, MF is administered via a dry-powder inhaler that contains multiple doses. As a preparation that would be more cost-effective, single-dose MF capsules were developed in Brazil. The objective of the present study was to evaluate the efficacy and safety of the two inhalers for MF administration in patients with asthma. METHODS: A randomized, multicenter, open-label, parallel-group clinical trial involving 74 adult patients with moderate, persistent asthma who were randomized into two groups to receive approximately 400 µg of MF once a day for 60 days, either via the multiple-dose inhaler or via the newly developed single-dose inhaler. RESULTS: No significant differences were observed between the two groups regarding the primary endpoints (FEV1 and rescue medication use) or the secondary endpoints (morning PEF, tolerability, and safety, the last as assessed on the basis of hypothalamic-pituitary-adrenal axis function). CONCLUSIONS: The use of the single-dose inhaler developed in Brazil for MF administration is as effective and safe as is that of a standard inhaler in the treatment of patients with asthma.
Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Anti-Inflammatory Agents/administration & dosage , Asthma/drug therapy , Dry Powder Inhalers/standards , Pregnadienediols/administration & dosage , Administration, Inhalation , Analysis of Variance , Dry Powder Inhalers/methods , Forced Expiratory Volume/drug effects , Statistics, NonparametricABSTRACT
<p><b>OBJECTIVE</b>To evaluate the outcome of mometasone furoate nasal spray (MFNS) used for 3 months on non-allergic rhinitis (NAR).</p><p><b>METHODS</b>In this multicenter study, NAR patients were enrolled from eight hospitals and received MFNS 200 microgram once daily for 3 months. The patients were followed-up for three times (at baseline, month 1 and month 3) to record the symptom scores and nasal endoscopic appearances. At the same time, the adverse events frequency was recorded and analyzed.</p><p><b>RESULTS</b>A total of 188 NAR cases were enrolled in the study. The total nasal symptom score assessment descended significantly at month 1 (1.70 ± 0.75) and month 3 (0.95 ± 0.79) visits versus at baseline (2.67 ± 0.68, Z value were from -11.603 to -10.491, all P < 0.01). The individual symptoms, including nasal stuffiness, nasal discharge, nasal stuffiness-related dizziness or headache, hyposmia, sleep quality, daily life activity, work or study efficiency, mental status, and whole body fatigue, also showed less scores at month 1 and month 3 visits versus at baseline (Z value were from -11.313 to -6.802, all P < 0.01). At the same time, nasal mucosal appearances assessed by endoscopy had lower scores at month 1 (1.40 ± 0.62) and month 3 (0.75 ± 0.71) visits versus at baseline (2.27 ± 0.73, Z value were from -11.484 to -10.002, all P < 0.01). Additionally, adverse events were only observed in 5.3% cases with light rhinorrhagia and nasal dryness. No other side effect was found.</p><p><b>CONCLUSIONS</b>A 3-months administration of intranasal mometasone can effectively and safely improve NAR patients' clinical symptom and nasal mucosal appearances.</p>
Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Anti-Allergic Agents , Therapeutic Uses , Mometasone Furoate , Nasal Sprays , Pregnadienediols , Therapeutic Uses , Rhinitis , Classification , Drug Therapy , Treatment OutcomeABSTRACT
<p><b>OBJECTIVE</b>To evaluate the effects of nasal mometasone furoate on moderate to severe allergic rhinitis.</p><p><b>METHODS</b>Patients with moderate to severe allergic rhinitis were enrolled and received mometasone furoate nasal spray 200 microg once daily for four weeks. Four hundreds and sixty-three patients completed the study. We weekly interviewed the patients to evaluate the symptoms, and the affection of disease on night sleep and daily life. Mini Rhinoconjunctivitis Quality of Life Questionnaire (Mini-RQLQ) and Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) were used to evaluate the quality of life.</p><p><b>RESULTS</b>The individual and total symptomatic scores of week 1, week 2 and week 4 decreased compared with baseline. The scores of Mini-RQLQ and NRQLQ of week 1, week 2 and week 4 decreased compared with baseline too. The scores of the next visit were significantly lower than those of the previous visit (P < 0.01).</p><p><b>CONCLUSIONS</b>A four-week administration of mometasone furoate nasal spray can effectively treat allergic rhinitis.</p>
Subject(s)
Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Young Adult , Administration, Intranasal , Anti-Allergic Agents , Therapeutic Uses , Mometasone Furoate , Pregnadienediols , Therapeutic Uses , Quality of Life , Rhinitis, Allergic, Perennial , Drug Therapy , Surveys and QuestionnairesABSTRACT
Topical corticosteroids have been the first line treatment in children with eczema. Efforts to develop new topical glucocorticoids with reduce systemic bioactivity help to treat them. Mometasone furoate 0.1% has been found to be efficacious in children with atopic dermatitis. To evaluate the therapeutic efficacy, safety and tolerability of mometasone furoate 0.1% cream, ointment and lotion in childhood eczema. The study was conducted from Oct 2007 to Jan 2008 at the outpatient department of dermatology at Abbasi Shaheed Hospital, Karachi. A total of 50 children, aged >12 years, of either sex with all types of childhood eczema were included in the study and those with infection, complication like scars, atrophy, striae, etc, known hypersensitivity to corticosteroids and on any other medicaments were excluded. Parents of children were instructed to apply a thin layer with gentle rubbing twice daily for three weeks. Fingertip unit [FTU] was demonstrated to parents. Tubes of mometasone furoate 0.1% cream, ointment and lotion were given to parents according to the need. Emollient was applied twice daily. Children were followed up at 3, 6 and 12 weeks. SPSS - 13.0 was used for statistical analysis. Friedman test was applied to compare the significance of results at p<0.05. Out of 50 patients enrolled, at 3 weeks of follow-up only 43 reported. 29 [67% showed improvement and 14 [32%] fully resolved. At 6 weeks 32 [74.4%] had complete resolution and 7 [16.2%] had improved, but at 12 weeks only 25 patients [58%] had resolved and 6 patients [13.9%] relapsed, while 2 patients were gradually improving. Efficacy in resolution of sign/symptoms on 12 weeks was [p<0.001]. No cutaneous or systemic side effects were seen. Mometasone furoate 0.1% cream, ointment and lotion are found to be effective, safe and highly tolerable in childhood eczema and the compound was found equally safe in infants
Subject(s)
Humans , Male , Female , Pregnadienediols , Pregnadienediols/administration & dosage , Child , Glucocorticoids , Administration, Cutaneous , Treatment Outcome , Pregnadienediols/toxicity , OintmentsABSTRACT
Presentamos un caso de liquen simple crónico vulvar izquierdo, en una paciente con diagnóstico psiquiátrico de trastorno bipolar, tratado repetidamente como micosis. Se realizó biopsia que confirmó el diagnóstico y se trató exitosamente con antihistamínicos orales y corticoides tópicos.
Subject(s)
Female , Adult , Humans , Neurodermatitis/diagnosis , Neurodermatitis/drug therapy , Vulva/pathology , Chronic Disease , Chlorpheniramine/therapeutic use , Neurodermatitis/pathology , PregnadienediolsABSTRACT
BACKGROUND AND AIMS: Topical glucocorticoid formulations are widely used for effective treatment and control of a variety of dermatoses. Mometasone furoate is a newer corticoid that has high potency but low systemic toxicity. Pharmaceutical factors are known to significantly influence potency and systemic absorption of topically applied glucocorticoids. We studied the potency of "Elocon", a topical formulation of mometasone furoate, compared with two other branded formulations of the same corticoid. METHODS: Corticoid potency was measured by employing a pharmacodynamic parameter of an inhibitory effect of the corticoid on post-ischemic-reactive-hyperemic-response (PIRHR) in human forearm skin under occlusive dressing. The PIRHR was expressed in terms of % increase in the skin blood flow (SBF) as measured with laser doppler velocimetry (LDV). RESULTS : All three active branded formulations of mometasone furoate produced significant inhibition of PIRHR. The AUC(0-2 min) of PIRHR was ( Mean +/- SEM ), Control = 213.52 +/- 11.80, Placebo = 209.77 +/- 19.31, Formulation A = 119.83 +/- 13.71, Formulation C = 53.67 +/- 4.85 and Formulation D = 111.46 +/- 22.87. Formulation "C" exhibited significantly higher topical anti-inflammatory potency than formulations "A" or "D". CONCLUSIONS: Thus, branded formulations of the same glucocorticoid, mometasone furoate significantly differed in their topical anti-inflammatory potency. "Elocon" was significantly more potent than the two other branded formulations studied.
Subject(s)
Administration, Topical , Adult , Analysis of Variance , Area Under Curve , Chemistry, Pharmaceutical , Female , Forearm , Glucocorticoids/administration & dosage , Humans , Laser-Doppler Flowmetry , Male , Pregnadienediols/administration & dosage , Reference Values , Sensitivity and Specificity , Single-Blind Method , Skin/drug effects , Skin Absorption/drug effectsABSTRACT
Atopic dermatitis is a common skin disease in Thai children. The treatment of atopic dermatitis requires topical corticosteroids, emollients, systemic antihistamine as well as avoidance of the precipitating factors. A double blind multicenter placebo controlled study was conducted to assess the therapeutic efficacy of topical mometasone furoate 0.1 per cent cream in combination with loratadine syrup. Forty-eight patients, 23 boys and 25 girls, mean age 73.67 months, with atopic dermatitis were included in the study. The severity of the disease was measured by using the SCORAD index including the degree of erythema, dryness, edema/papulation, oozing/crusting, lichenification, and excoriation. Total area involved was measured and a target area of dermatitis was selected for specific evaluation. The degree of clinical signs and pruritic symptom was graded. The sensation of pruritus, disturbance of sleep due to pruritus, and feeling of sleepiness in the morning were recorded. Mometasone furoate 0.1 per cent cream was applied to all patients once daily. One group received loratadine syrup and another group received placebo syrup. They were followed-up on day 5, 8 and 15. The severity of atopic dermatitis and pruritus significantly decreased after 14 days of treatment in both groups (p < 0.001). There was no difference in therapeutic response between the loratadine and placebo groups (p = 0.99). All signs examined had decreased by the end of the study. The result demonstrated that 0.1 per cent mometasone therapy is very effective for treating childhood atopic dermatitis. Loratadine did not show beneficial effect when combined with good topical corticosteroid but it was safe and had no serious side effect on the children.